CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
SU011248 capsuledrug
Likely dose
SU011248 capsule 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00254540
NCT00254540Phase 2Completed
CompareCT.gov

Phase II Study Of Single-Agent SU011248 In The Treatment Of Patients With Renal Cell Carcinoma

Pfizer·interventional·Posted Nov 16, 2005·Updated Feb 23, 2010

In Brief

A Phase 2 clinical trial evaluating SU011248 capsule for Carcinoma, Renal Cell. Completed, enrolled 51 participants across 11 sites.

Detailed Summary

To determine the objective tumor response of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks and 2 weeks rest, repeated every 6 weeks in patients with metastatic Renal Cell Cancer (RCC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 16, 2005
Enrollment StartDec 1, 2005
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 20.6 years ago

Interventions

SU011248 capsuledrug

50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops